Man

Sergio Quezada

Professiorial Research Fellow

UCL Cancer Institute

London, Reino Unido

Líneas de Investigación


Immunology, anti-CTLA-4, anti-PD-1 and other immune-modulatory antibodies targering co-inhibitory and co-stimulatory pathway

Educación

  •  Biochemistry, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 1999
  •  Immunology, Dartmouth Medical School. Estados Unidos, 2004

Experiencia Académica

  •   Postdoc Full Time

    Dartmouth Medical School, New Hampshire

    New Hampshire, Estados Unidos

    2004 - 2004

  •   Postdoc Full Time

    Memorial Sloan-Kettering Cancer Center

    New York, Chile

    2005 - 2010

Experiencia Profesional

  •   Professorial Research Fellow and Group Leader Other

    University College London Cancer Institute.

    London, Reino Unido

    2010 - A la fecha

  •   Adjunct investigator Other

    The Royal Marsden, NHS Foundation Trust.

    London, Chile

    2012 - A la fecha

  •   Immunology Lead Other

    UCL/Manchester CRUK Lung Cancer Centre of Excellence

    Manchester, Reino Unido

    2014 - A la fecha


 

Article (36)

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes
TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors
Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report
CMV promotes recipient T-cell immunity following reduced-intensity T-cell-depleted HSCT, significantly modulating chimerism status
Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity
Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure
TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells
Translational Implications of Tumor Heterogeneity
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
An antitumor boost to TH9 cells
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
Resolution of acute inflammation bridges the gap between innate and adaptive immunity
Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Tumour heterogeneity and immune-modulation
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas
PD-1 blockade: promoting endogenous anti-tumor immunity
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
Tumor-reactive CD4 + T cells: plasticity beyond helper and regulatory activities
Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)
Tumor-reactive CD4 + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation
Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism
Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis
Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation
The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning

Patent (2)

Combination immunotherapy for the treatment of cancer
Regulatory t cell mediator proteins and uses thereof

Proyecto (7)

Cancer Immunotherapy Catalyst Network
Testing bi-specific antibodies in syngeneic mouse models
Evaluation Of Immunomodulatory Bispecific Antibodies In Murine Models
ERC- FP7 Health 2013 Innovation
Exploring And Exploiting Mechanisms Of Response And Resistance To Ipilimumab And Other Novel Immune Modulatory Antibodies For Therapeutic Gain
Deciphering the immune and neoantigenic landscape of lung cancer and their relevance to cancer immunotherapy
Development and evaluation of check-point-targeting antibodies with enhanced activity based on Fc interactions and tumour microenvironment
45
Sergio Quezada

Professiorial Research Fellow

UCL Cancer Institute

London, Reino Unido